Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CENPE | Q02224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088641 | 0.85 | CSNK2A1 (0.72) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL14948760 | 0.85 | CSNK2A1 (0.53) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL12768177 | 0.84 | CSNK2A1 (0.70) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL6215544 | 0.84 | CSNK2A1 (1.00) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL3718847 | 0.84 | CSNK2A1 (0.70) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL3722004 | 0.84 | CSNK2A1 (0.70) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL10274466 | 0.84 | CSNK2A1 (0.51) | CSNK2A1MEN1KMT2ALMNAS1PR3 | |
| SCHEMBL16606256 | 0.82 | CSNK2A1 (0.49) | CSNK2A1MEN1KMT2ALMNAGAA | |
| SCHEMBL20820454 | 0.82 | RORC (0.53) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL25144732 | 0.81 | CSNK2A1 (0.66) | CSNK2A1MEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | CSNK2A1 489/4885MEN1 4265/4885KMT2A 1554/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | CSNK2A1 4734/4885MEN1 1444/4885KMT2A 3013/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | CSNK2A1 447/4885MEN1 3019/4885KMT2A 2593/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CSNK2A1 67/4885MEN1 4673/4885KMT2A 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.